West Pharmaceutical Services Reclassification from AOCI, Net of Tax decreased by 266.7% to -$500.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 66.7%, from -$300.00K to -$500.00K.
A large reclassification indicates the realization of previously deferred gains or losses, impacting current period earnings.
The amount of gains or losses previously recognized in accumulated other comprehensive income that are reclassified into...
Standard accounting metric; comparable to reclassification adjustments in the statement of comprehensive income.
tmo_reclassification_from_aoci_net_of_tax| Q2 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$2.60M | -$800.00K | -$200.00K | -$13.40M | -$400.00K | -$2.20M | -$3.30M | -$1.00M | -$400.00K | -$300.00K | -$300.00K | $300.00K | -$500.00K |
| QoQ Change | — | +69.2% | +75.0% | <-999% | +97.0% | -450.0% | -50.0% | +69.7% | +60.0% | +25.0% | +0.0% | +200.0% | -266.7% |
| YoY Change | — | — | +92.3% | — | +50.0% | <-999% | +75.4% | -150.0% | +81.8% | +90.9% | +70.0% | +200.0% | -66.7% |